Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Free Cash Flow (2022 - 2025)

Coya Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 79.3% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$12.1 million, down 19.98%, while the annual FY2024 figure was -$10.3 million, 8.04% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$1.1 million at Coya Therapeutics, up from -$5.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.1 million in Q1 2024 and bottomed at -$5.8 million in Q2 2025.
  • The 4-year median for Free Cash Flow is -$2.2 million (2023), against an average of -$2.6 million.
  • The largest annual shift saw Free Cash Flow soared 155.54% in 2024 before it tumbled 231.8% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$2.2 million in 2022, then dropped by 0.81% to -$2.2 million in 2023, then decreased by 7.53% to -$2.4 million in 2024, then surged by 53.08% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Free Cash Flow are -$1.1 million (Q3 2025), -$5.8 million (Q2 2025), and -$2.8 million (Q1 2025).